112 related articles for article (PubMed ID: 1859903)
1. [Oral contraception and benign breast diseases: point of view of the epidemiologist].
Lê MG; Charreau I
Bull Cancer; 1991; 78(4):357-63. PubMed ID: 1859903
[TBL] [Abstract][Full Text] [Related]
2. Oral contraception and breast pathology.
Ragni N; Boccardo E; Viglino S; Larosa E
Acta Eur Fertil; 1981 Jun; 12(2):141-63. PubMed ID: 6794288
[TBL] [Abstract][Full Text] [Related]
3. The Royal College of General Practitioners' Oral Contraception Study: some recent observations.
Kay CR
Clin Obstet Gynaecol; 1984 Dec; 11(3):759-86. PubMed ID: 6509858
[TBL] [Abstract][Full Text] [Related]
4. [Oral contraceptives and breast tumors: which pill?].
La Vecchia C
Riv Inferm; 1984 Mar; 3(1):54-6. PubMed ID: 6431597
[TBL] [Abstract][Full Text] [Related]
5. [Contraception without risk of breast disease: epidemiologic and physiopathologic arguments].
Le Coutour X
NPN Med; 1985 Apr; 5(88):471-6. PubMed ID: 12315304
[TBL] [Abstract][Full Text] [Related]
6. Researchers can now investigate long-term effects of OCs on cancer.
Rubin GL; Peterson HB
Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
[TBL] [Abstract][Full Text] [Related]
7. [Contraception and breast cancer].
Kottler ML; Gorins A
Rev Fr Gynecol Obstet; 1991 Jan; 86(1):21-6. PubMed ID: 2068480
[TBL] [Abstract][Full Text] [Related]
8. Multiplicity of benign breast lesions is a risk factor for progression to breast cancer.
Worsham MJ; Raju U; Lu M; Kapke A; Cheng J; Wolman SR
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5474-9. PubMed ID: 17875777
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of oral contraceptives and the risk of breast cancer.
Webster L
J Reprod Med; 1986 Jun; 31(6 Suppl):540-5. PubMed ID: 3723486
[TBL] [Abstract][Full Text] [Related]
10. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
Tzingounis V; Cardamakis E; Ginopoulos P; Argiropoulos G
Anticancer Res; 1996; 16(6C):3997-4000. PubMed ID: 9042326
[TBL] [Abstract][Full Text] [Related]
11. Age-specific differences in the relationship between oral contraceptive use and breast cancer.
Wingo PA; Lee NC; Ory HW; Beral V; Peterson HB; Rhodes P
Obstet Gynecol; 1991 Aug; 78(2):161-70. PubMed ID: 2067757
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives and breast cancer.
Gay JW; Cardwell MS
Mo Med; 1990 Oct; 87(10):763-7. PubMed ID: 2259330
[TBL] [Abstract][Full Text] [Related]
13. [New discoveries on oral contraceptives and risk of breast cancer. International data show a moderate increase in risk].
Persson I
Lakartidningen; 1996 Dec; 93(50):4613-6. PubMed ID: 8999253
[TBL] [Abstract][Full Text] [Related]
14. Update on cancer risk and oral contraceptives.
Engel NS
MCN Am J Matern Child Nurs; 1990; 15(1):37. PubMed ID: 2105427
[TBL] [Abstract][Full Text] [Related]
15. The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.
Collins LC; Baer HJ; Tamimi RM; Connolly JL; Colditz GA; Schnitt SJ
Cancer; 2006 Sep; 107(6):1240-7. PubMed ID: 16902983
[TBL] [Abstract][Full Text] [Related]
16. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
Jernström H; Loman N; Johannsson OT; Borg A; Olsson H
Eur J Cancer; 2005 Oct; 41(15):2312-20. PubMed ID: 16118051
[TBL] [Abstract][Full Text] [Related]
17. Risks of oral contraceptive use in women over 35.
Stenchever MA
J Reprod Med; 1993 Dec; 38(12 Suppl):1030-5. PubMed ID: 8120860
[TBL] [Abstract][Full Text] [Related]
18. Results of oral contraceptive epidemiologic studies regarding neoplastic and cardiovascular effects.
Grimes DA
Int J Fertil; 1989; 34 Suppl():27-33. PubMed ID: 2576254
[TBL] [Abstract][Full Text] [Related]
19. Combined progestin and estrogen (oral), and other forms of hormonal contraception.
McPherson K
Curr Opin Obstet Gynecol; 1991 Aug; 3(4):486-90. PubMed ID: 1878505
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer and oral contraceptives: critique of the proposition that high potency progestogen products confer excess risk.
Sturtevant FM
Biomed Pharmacother; 1984; 38(8):371-9. PubMed ID: 6525434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
